CAMBRIDGE, Mass., Aug. 4, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today that it will participate in the 2011 Canaccord Genuity Growth Conference. Marc Beer, CEO of Aegerion, is scheduled to present on Thursday, August 11, 2011, at 9:00 a.m. ET.
A live webcast of the presentation will be available and can be accessed for 90 days following the conference by visiting the "Investors" section of Aegerion's website, www.aegerion.com.
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders. The Company's lead product, lomitapide, is in Phase III clinical development. Lomitapide is initially being developed to treat patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH. The Company also plans to initiate a clinical program for lomitapide to treat patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia.